Skip to content
Catalyst

knowcompoundsmethylphenidate

Specimen compound organic compound

Methylphenidate

fig. 1Methylphenidate · findings by direction and evidence strength
Formula
C14H19NO2
Molar mass
233.307 g/mol

↑ raised 2 findings in 2 endpoints · – no difference found 3 in 3

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
0
Limited
1
Very limited
4
Insufficient
0

How to read these marks

Fig. 2 Methylphenidate CHEBI:6887 4 endpoints 5 findings
×1.60
Labels
CompoundInspector

Methylphenidate

Most findings

  • Health-related quality of life×2
  • Hamilton Depression Rating Scale (HDRS) total score×1
  • Serious adverse event incidence×1
  • Working memory performance×1

2 reference statements, not drawn · 29 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. Working memory performance
  2. Health-related quality of lifecontested
  3. Hamilton Depression Rating Scale (HDRS) total score
  4. Serious adverse event incidence
fig. 3 · 4 endpoints · 5 findingscontested · an endpoint whose findings disagree

02 · contested · 1 endpoint

Where the findings disagree

  1. 012 findings

    Health-related quality of life

    – no difference found
    1
    ↑ raised
    1

03 · findings

What methylphenidate moved, and by how much

  • OR odds ratio · RR risk ratio · MD mean difference · SMD standardised mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction
Strength, at least

5 shown

  1. Working memory performanceMoved: raisesEffect, as reportedOR1.67[1.09 to 2.57]Evidence: LimitedPaper: PMID 399307132025
    Who
    Healthy adults aged 21-45 years; single 10 mg dose against placebo in a randomised double-blind crossover with one-week washout; main effect of treatment pooled over the 20-minute and 130-minute assessments
    Dose studied
    10 mg methylphenidate (Ritalin), single dose

    A significant main effect of treatment was observed for numeric working memory accuracy, whereby accuracy improved (better performance: F(1,96) = 8.76, p = 0.004) following methylphenidate (M = 96.47, SD ± 2.83) administration relative to placebo (M = 94.45, SD ± 4.43, with an odds ratio of 1.67 (95%CI: 1.09–2.57).).”

    Quoted verbatim from Acute Administration of 10 mg Methylphenidate on Cognitive Performance and Visual Scanning in Healthy Adults: Randomised, Double-Blind, Placebo-Controlled Study.crossoverPermalink
  2. Serious adverse event incidenceMoved: no difference foundEffect, as reportedRR0.8[0.39 to 1.67]Evidence: Very limitedPaper: PMID 413423062025
    Who
    children and adolescents with ADHD; primary outcome (serious adverse events) · n = 3,673
    Dose studied
    not reported

    Methylphenidate may not affect serious adverse events (risk ratio (RR) 0.80, 95% CI 0.39 to 1.67; I² = 0%; 26 trials, 3673 participants; very low-certainty evidence).”

    Quoted verbatim from Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).meta-analysisPermalink
  3. Hamilton Depression Rating Scale (HDRS) total scoreMoved: no difference foundEffect, as reportedMD2.8[−0.09 to 5.69]Evidence: Very limitedPaper: PMID 334600482021
    Who
    adults with ADHD, immediate-release methylphenidate versus placebo; secondary outcome (depression) · n = 19
    Dose studied
    not reported

    There is no clear evidence of an effect on anxiety (MD -0.20, 95% CI -4.84 to 4.44; 1 trial, 19 participants; change scores; Hamilton Anxiety Scale (HAM-A; scored from 0 to 56); very low-certainty evidence) or depression (MD 2.80, 95% CI -0.09 to 5.69; 1 trial, 19 participants; change scores; Hamilton Depression Scale (HAM-D; scored from 0 to 52); very low-certainty evidence) in analyses comparing IR methylphenidate with placebo.”

    Quoted verbatim from Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.RCTPermalink
  4. Health-related quality of lifecontestedMoved: raisesEffect, as reportedSMD0.61[0.42 to 0.8]Evidence: Very limitedPaper: PMID 265995762015
    Who
    Children and adolescents aged 18 years or younger with ADHD, parent-reported quality of life, meta-analysis of three trials against placebo or no intervention
    Dose studied
    not reported

    The change reported in a meta-analysis of three trials corresponds to a MD of 8.0 points (95% CI 5.49 to 10.46) on the CHQ, which suggests that methylphenidate may improve parent-reported quality of life (SMD 0.61, 95% CI 0.42 to 0.80; 3 trials, 514 participants; very low-quality evidence).”

    Quoted verbatim from Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).meta-analysisPermalink
  5. Health-related quality of lifecontestedMoved: no difference foundEffect, as reportedSMD0.4[−0.03 to 0.83]Evidence: Very limitedPaper: PMID 413423062025
    Who
    children and adolescents with ADHD; secondary outcome (quality of life), instrument not named by the review · n = 608
    Dose studied
    not reported

    Methylphenidate may improve teacher-rated general behaviour versus placebo (SMD -0.62, 95% CI -0.91 to -0.33; I² = 68%; 7 trials 792 participants; very low-certainty evidence), but may not affect quality of life (SMD 0.40, 95% CI -0.03 to 0.83; I² = 81%; 4 trials, 608 participants; very low-certainty evidence).”

    Quoted verbatim from Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).meta-analysisPermalink

No dose is advised.

  • OR odds ratio · RR risk ratio · MD mean difference · SMD standardised mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

04 · identity

Structure

Charge
0
2D depiction
A class in ChEBI, no single structure

05 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reference statements
201 Compounddexmethylphenidate, methyl (S)-phenyl[(S)-piperidin-2-yl]acetateinferred, one hop from methylphenidate
2Reference statements

What the reference databases state

Evidence key

Statements

2 statements

methylphenidate is converted to each

06 · the record

Sources

1,138

papers screened for methylphenidate

admitted
5
read and discarded
207
not read yet
926

The screening record, every paper and why

Sources cited

4 papers · 5 findings

1 admitted at screening, no finding yet

Show every paper citedHide the papers cited